Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)-Reference-Cited by-同舟云学术

Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

Published:2020-11-18 Issue:4 Volume:27 Page:975-982
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Sharma Priyanka,Kimler Bruce F.^ORCID,O'Dea Anne,Nye Lauren,Wang Yen Y.,Yoder Rachel,Staley Joshua M.^ORCID,Prochaska Lindsey,Wagner Jamie,Amin Amanda L.^ORCID,Larson Kelsey^ORCID,Balanoff Christa^ORCID,Elia Manana,Crane Gregory,Madhusudhana Sheshadri,Hoffmann Marc,Sheehan Maureen,Rodriguez Roberto,Finke Karissa,Shah Rajvi,Satelli Deepti,Shrestha Anuj,Beck Larry,McKittrick Richard,Pluenneke Robert,Raja Vinay,Beeki Venkatadri,Corum Larry,Heldstab Jaimie,LaFaver Stephanie,Prager Micki,Phadnis Milind,Mudaranthakam Dinesh Pal^ORCID,Jensen Roy A.^ORCID,Godwin Andrew K.^ORCID,Salgado Roberto,Mehta Kathan,Khan Qamar

Funder

University of Kansas Cancer Center

Breast Cancer Research Foundation

National Institute of General Medical Sciences

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond cisplatin: New frontiers in metallodrugs for hard-to-treat triple negative breast cancer;Coordination Chemistry Reviews;2024-01

2. Adipocyte-derived exosomes promote the progression of triple-negative breast cancer through circCRIM1-dependent OGA activation;Environmental Research;2023-12

3. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial;Annals of Oncology;2023-12

4. The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review;Cureus;2023-11-30

5. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer;JAMA Oncology;2023-11-22